Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SurModics (SRDXResearch Report) and Axsome Therapeutics (AXSMResearch Report) with bullish sentiments.

SurModics (SRDX)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on SurModics, with a price target of $70.00. The company’s shares closed last Thursday at $32.86.

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 6.9% and a 49.9% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Lifecore Biomedical, and US Physical Therapy.

SurModics has an analyst consensus of Moderate Buy, with a price target consensus of $58.00, representing a 76.5% upside. In a report issued on November 4, Needham also maintained a Buy rating on the stock with a $46.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Axsome Therapeutics (AXSM)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics today and set a price target of $80.00. The company’s shares closed last Thursday at $53.26.

According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of -0.3% and a 46.3% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Harmony Biosciences Holdings, and Intra-Cellular Therapies.

Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $100.09, implying an 87.9% upside from current levels. In a report issued on November 7, Jefferies also maintained a Buy rating on the stock with a $90.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SRDX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More